🇺🇸 FDA
Patent

US 11220524

Selective inhibitors of protein arginine methyltransferase 5 (PRMT5)

granted A61PA61P35/00

Quick answer

US patent 11220524 (Selective inhibitors of protein arginine methyltransferase 5 (PRMT5)) held by Prelude Therapeutics, Incorporated expires Mon Jan 06 2042 00:00:00 GMT+0000 (Coordinated Universal Time). Status: granted.

Key facts

Applicant
Prelude Therapeutics, Incorporated
Grant date
Tue Jan 11 2022 00:00:00 GMT+0000 (Coordinated Universal Time)
Expiration
Mon Jan 06 2042 00:00:00 GMT+0000 (Coordinated Universal Time)
Claims
20
CPC classes
A61P, A61P35/00